Filed: 2/14/2025ACC: 0001104659-25-013923
📋 What this filing means
FORESITE CAPITAL MANAGEMENT IV, LLC filed this quarterly 13F‑HR report disclosing 4 equity positions with a total reported market value of $108.80M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
4
Positions
$108.80M
Total AUM (reported)
15.45M
Total Shares
Allocation by class
COM$108.80M100.0%
Portfolio Concentration
Top 3$104.68M96.2%
4–10$4.12M3.8%
Top 3 weight
96.2%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 15.45M
Sole
Full voting authority
15.45M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole4
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings4
Rows:
Pharvaris N.V.
SOLEShares4.40M
TypeSH
Market value$84.31M
77.49%
Sole
4.40M
Shared
0.00
None
0.00
Kura Oncology, Inc.
SOLEShares1.73M
TypeSH
Market value$15.04M
13.83%
Sole
1.73M
Shared
0.00
None
0.00
Lyell Immunopharma, Inc.
SOLEShares8.32M
TypeSH
Market value$5.33M
4.90%
Sole
8.32M
Shared
0.00
None
0.00
Relay Therapeutics Inc.
SOLEShares1M
TypeSH
Market value$4.12M
3.79%
Sole
1M
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Pharvaris N.V.SOLE | COM | 4.40M | SH | $84.31M 77.49% | 4.40M | 0.00 | 0.00 |
Kura Oncology, Inc.SOLE | COM | 1.73M | SH | $15.04M 13.83% | 1.73M | 0.00 | 0.00 |
Lyell Immunopharma, Inc.SOLE | COM | 8.32M | SH | $5.33M 4.90% | 8.32M | 0.00 | 0.00 |
Relay Therapeutics Inc.SOLE | COM | 1M | SH | $4.12M 3.79% | 1M | 0.00 | 0.00 |